Polycystic ovary syndrome is one of the most common endocrine disorders affecting women of reproductive age, characterized by irregular or absent ovulation, elevated androgens, and polycystic ovarian morphology. Because the hypothalamic-pituitary-ovarian axis behaves differently in these patients, with altered gonadotropin secretion patterns and often exaggerated ovarian sensitivity to hormonal cues, reproductive endocrinologists have debated for decades whether a high baseline LH level helps or harms women undergoing controlled ovarian stimulation. Some earlier hypotheses implicated elevated LH in impaired oocyte quality and reduced implantation, prompting some clinics to suppress LH before treatment. Others argued that LH plays a supportive role in theca cell androgen production, which fuels estradiol synthesis in the granulosa cells that nurture developing follicles. Until now, direct clinical evidence in PCOS patients undergoing modern IVF and intracytoplasmic sperm injection protocols has remained thin.

The research team, led by first authors Jun Liu, Xiaoyu Yu, and Fengjuan Zhang, analyzed records from 162 women with PCOS and 120 controls who all underwent IVF or ICSI followed by embryo transfer at a single reproductive medicine center. To probe whether the starting LH level mattered, the investigators stratified the PCOS patients into high-LH and low-LH groups and then systematically compared their endocrine profiles, ovarian stimulation responses, embryological parameters, endometrial characteristics, and pregnancy outcomes. The ethics committee of Sichuan Provincial Women’s and Children’s Hospital approved the protocol, and all participants provided informed consent, with the study conducted under the Declaration of Helsinki.

The baseline comparisons confirmed the expected metabolic and endocrine signature of PCOS: women with the syndrome had higher body mass index, higher testosterone, and markedly elevated anti-Müllerian hormone, the marker that reflects the enlarged pool of small antral follicles that defines the condition. Yet when it came to the mechanics of stimulation, the two PCOS subgroups diverged in an instructive way. Women in the high-LH group displayed a higher antral follicle count, needed lower total gonadotropin doses to drive multifollicular development, and reached higher estradiol concentrations on the day of the hCG trigger. Together these three signals point in one direction: a higher starting LH level was associated with enhanced ovarian responsiveness, meaning the ovaries of these women answered the stimulation drugs more vigorously and more economically.

Crucially, however, that heightened responsiveness did not translate into better reproductive outcomes. Fertilization rates were statistically indistinguishable between the high- and low-LH PCOS groups, as were embryo quality measures and the proportion of high-quality embryos produced per cycle. The stimulation duration itself was similar across groups, indicating that LH status did not accelerate or delay follicular maturation in any clinically meaningful way. When the investigators tracked the downstream pregnancy endpoints, the pattern held firm: biochemical pregnancy rates, clinical pregnancy rates, and live birth rates showed no significant differences attributable to baseline LH. The hormone that visibly reshaped the stimulation cycle left the bottom line untouched.

To place these subgroup findings in a broader context, the authors applied logistic regression modeling to identify independent predictors of clinical pregnancy across the cohort. The result was striking in what it excluded as much as in what it included. Body mass index and anti-Müllerian hormone emerged as significant independent predictors, while baseline LH failed to reach predictive significance. In practical terms, this means a clinician weighing the prognosis for a PCOS patient about to start an IVF cycle would gain more from noting her weight and her AMH level than from her pre-treatment LH value. The study also flagged a sobering signal on the other side of the pregnancy equation: miscarriage risk was elevated in PCOS patients overall compared with controls, and this risk appeared particularly concentrated in the low-LH subgroup, hinting that insufficient LH activity may be associated with a less favorable early pregnancy environment even if it does not impede conception itself.

What might explain the apparent paradox that LH shapes responsiveness without affecting outcomes? The researchers turned to an animal model for mechanistic insight, establishing a PCOS rat model and examining the ovaries for changes in the expression of the two gonadotropin receptors that orchestrate follicular development: the follicle-stimulating hormone receptor, FSHR, and the luteinizing hormone receptor, LHR. In the granulosa cells, the specialized support cells surrounding each oocyte, the PCOS rats showed a coordinated remodeling of receptor expression, with FSHR decreased and LHR increased. This local shift suggests that under PCOS conditions the ovary recalibrates its sensitivity to the two pituitary hormones, potentially compensating for systemic hormonal disturbances in ways that alter how external stimulation protocols are experienced at the cellular level.

The receptor findings carry implications beyond the laboratory. If granulosa cells in PCOS ovaries downregulate FSHR while upregulating LHR, the conventional assumption that FSH-driven stimulation proceeds through the same molecular machinery in PCOS and non-PCOS ovaries becomes questionable. Elevated local LHR expression could partly explain why high-LH PCOS patients respond so exuberantly to exogenous gonadotropins, achieving robust estradiol rises with lower drug doses. At the same time, the dysregulation of this local signaling network may contribute to the disordered folliculogenesis that characterizes the syndrome, and could interact with the elevated miscarriage risk the study documented, though the authors are careful to present the animal data as suggestive of dysregulated gonadotropin signaling rather than proof of a specific causal chain running from receptor expression to pregnancy loss.

For patients, the clinical takeaway is genuinely liberating. Women with PCOS who discover a high LH value on their pre-treatment blood panel need not fear that this number has doomed their cycle, nor should those with low LH assume their chances are compromised at the outset. The study indicates that baseline LH in PCOS is a marker of ovarian responsiveness, useful perhaps for tailoring gonadotropin starting doses and anticipating hyper-response, but not a determinant of fertilization, implantation, clinical pregnancy, or live birth. Meanwhile, the identification of BMI and AMH as independent predictors reinforces what a growing body of literature has argued: weight management and ovarian reserve assessment deserve central places in fertility counseling for PCOS patients. Elevated AMH, though it reflects the abundant follicle pool that makes PCOS ovaries so responsive, emerged alongside BMI as a predictor of clinical pregnancy, underscoring the complex double-edged role this hormone plays in the syndrome.

As with all retrospective single-center studies, the findings come with caveats that invite future work. The cohort of 282 participants is substantial but retrospective design cannot exclude residual confounding, and stimulation protocols, laboratory conditions, and transfer strategies may vary across centers and eras. Nonetheless, the study’s dual design, combining a well-stratified clinical cohort with mechanistic receptor analysis in an animal model, gives it unusual breadth for the field. By demonstrating that the luteinizing hormone value on a pre-treatment lab slip tells a story about ovarian sensitivity but not about babies, the Chengdu team has helped refocus attention on the factors that truly move the needle for women with PCOS pursuing assisted reproduction, while opening a fresh line of inquiry into how the ovary’s own receptor landscape rewires itself in one of the most common hormonal disorders of our time.

Subject of Research: The effect of basal luteinizing hormone levels on IVF/ICSI-ET outcomes in women with polycystic ovary syndrome

Article Title: Effect of basal luteinizing hormone on IVF/ICSI-ET outcomes in patients with polycystic ovary syndrome: a retrospective study

Article References: Liu, J., Yu, X., Zhang, F., Liu, W., Zeng, J., & Wang, L. (2026). Effect of basal luteinizing hormone on IVF/ICSI-ET outcomes in patients with polycystic ovary syndrome: a retrospective study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02603-5

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02603-5

Keywords: polycystic ovary syndrome, luteinizing hormone, IVF, ICSI, embryo transfer, anti-Müllerian hormone, ovarian stimulation, live birth rate, miscarriage risk, granulosa cells, FSHR, LHR

The findings, drawn from nine randomized controlled trials encompassing 2,481 women with recurrent implantation failure, are cautiously encouraging. The researchers, led by Mohammadamin Parsaei of Tehran University of Medical Sciences, found that women whose embryos underwent laser-assisted hatching had significantly higher rates of clinical pregnancy, ongoing pregnancy, and live birth compared with women who received no such intervention. Perhaps most strikingly, the technique was associated with a significantly lower rate of miscarriage, and the live birth and miscarriage results carried moderate certainty in the researchers’ formal quality assessment, a level of confidence that is rare in this literature.

To understand why the technique exists at all, one has to look at the biology of the earliest days of embryonic development. Every embryo begins life encased in the zona pellucida, a glycoprotein shell that protects the oocyte and early embryo, mediates sperm recognition, and prevents premature implantation. As the embryo reaches the blastocyst stage, it must hatch from this shell, expanding, contracting, and finally rupturing it before it can make contact with the uterine lining. Scientists have long hypothesized that some embryos, particularly those cultured in the laboratory or derived from older oocytes with hardened or thickened zonae, may struggle to complete this escape, and that a laboratory-assisted exit could tip the balance toward successful implantation.

Assisted hatching began as a micromanipulation procedure in the late 1980s, when researchers first partially opened the zona pellucida to facilitate fertilization and later to aid hatching. Early methods relied on mechanical piercing or acidic chemical drilling, both of which carried risks of embryo damage and required considerable manual skill. The introduction of non-contact diode and ultraviolet lasers in the 1990s transformed the procedure: a focused beam could now thin a precise section of the shell, or drill a controlled opening, in seconds, with minimal handling and reproducible results. Today, laser-assisted hatching is performed in two main variants, zona thinning and zona drilling, and the new analysis examined both approaches in its subgroup analyses.

For the new study, the team searched PubMed, Web of Science, Scopus, and Embase on January 22, 2025, for randomized controlled trials comparing embryo transfer outcomes after laser-assisted hatching against controls specifically in women with recurrent implantation failure. They followed the PRISMA 2020 reporting guidelines, assessed risk of bias with the Cochrane RoB 2 tool, pooled outcomes using random-effects meta-analyses expressed as log odds ratios, and graded the certainty of the evidence with the GRADE framework. Publication bias was probed with funnel plots, Egger’s regression test, and the trim-and-fill method, while subgroup analyses stratified results by mean patient age, overall risk of bias, and the specific hatching technique used.

The headline numbers tell a consistent story. Clinical pregnancy was significantly more likely in the hatched group, with a log odds ratio of 0.643 and a 95 percent confidence interval of 0.267 to 1.019, though the underlying trials showed substantial heterogeneity and the certainty of this evidence was rated very low. Ongoing pregnancy showed a similar pattern, with a log odds ratio of 0.811 and very low certainty. Live birth, the outcome that matters most to patients, was significantly improved with a log odds ratio of 0.519 and remarkably low heterogeneity between studies, earning a moderate certainty rating. Miscarriage was significantly reduced, with a log odds ratio of minus 0.632, zero heterogeneity, and moderate certainty.

Not every result favored the intervention. Implantation rates per transferred embryo did not differ significantly between groups, with a log odds ratio of 0.691 whose confidence interval crossed zero and very high heterogeneity of 87.14 percent, suggesting the trials measured this outcome in markedly different ways. Multiple pregnancy rates per clinical pregnancy were also statistically indistinguishable between groups, with zero heterogeneity and moderate certainty, a finding that will reassure clinicians who have worried that weakening the zona pellucida might encourage the embryo to split into identical twins.

The divergence between the live birth and miscarriage results on one hand and the implantation result on the other is scientifically intriguing. If laser-assisted hatching does not measurably increase the proportion of embryos that implant, yet more pregnancies ultimately end in a take-home baby and fewer end in miscarriage, one possible interpretation is that the technique benefits embryos that would otherwise implant abnormally or fail shortly after attachment. The authors themselves, however, urge restraint, noting that the heterogeneity observed across trials and the generally low quality of the available studies mean these conclusions remain provisional, and that high-quality, large-scale randomized controlled trials are needed to confirm them.

The new analysis arrives amid a shifting regulatory and clinical landscape. The American Society for Reproductive Medicine’s 2022 guideline on assisted hatching concluded that the procedure should not be offered routinely or even as a treatment for patients with an anticipated poor prognosis, citing insufficient evidence of benefit. A 2021 Cochrane review of assisted hatching across all IVF and ICSI patients similarly found no clear benefit and raised concerns about possible harms. Yet those syntheses pooled broad populations, including many patients with no implantation problems at all, which may have diluted any genuine effect in the subgroup that matters. By restricting the analysis to women with documented recurrent implantation failure, the new study tests a more focused hypothesis, and its positive live birth finding stands in meaningful tension with the earlier, broader reviews.

For the roughly ten percent of IVF patients who experience repeated implantation failure, the practical takeaway is one of measured hope rather than a change in standard care. The evidence now suggests that laser-assisted hatching, a quick and technically straightforward laboratory procedure, may improve the odds of a live birth in this difficult population without increasing multiple pregnancies, and that it may reduce the heartbreak of miscarriage. But with several of the key outcomes graded at very low certainty, and with the field still lacking a universally agreed definition of recurrent implantation failure itself, patients and clinicians alike will be watching for the large, well-designed trials that the authors say are now essential. Until then, the laser remains a promising but unproven ally in one of fertility medicine’s most stubborn challenges.

Subject of Research: Laser-assisted hatching and embryo transfer outcomes in patients with recurrent implantation failure

Article Title: Outcomes of Embryo Transfer Following Laser-assisted Hatching in Patients with Recurrent Implantation Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Article References: Parsaei, M., Karimi, E., Seifi, P., Dehghan Tarzjani, M., & Tarafdari, A. (2026). Outcomes of Embryo Transfer Following Laser-assisted Hatching in Patients with Recurrent Implantation Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02219-z

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02219-z

Keywords: laser-assisted hatching, recurrent implantation failure, embryo transfer, in vitro fertilization, meta-analysis, live birth rate, miscarriage, zona pellucida, clinical pregnancy, assisted reproductive technology, randomized controlled trials, reproductive medicine